Kornimate/medical-research-clean huggingface dataset:
nsaids in sciatica nsaids in sciatica

Conditions: Sciatica

Summary: this study will evaluate whether treatment with naproxen 500 mg twice daily is superior to placebo for the improvement of leg pain in patients with sciatica. half of patients will receive naproxen while the other half will receive placebo.

sciatica is an established term for pain radiating from the lower back or buttock into the leg, commonly caused by a disc herniation. given their analgesic and anti-inflammatory mechanisms of action, nsaids (non-steroidal anti-inflammatory drugs) have been, and are still being regarded as standard therapy for sciatica. however, very few randomised controlled trials of nsaids have been undertaken in sciatica, and no study has showed clinically meaningful effects as compared to placebo. since nsaids involve the risk of serious gastrointestinal, vascular and renal side effects there is a strong need to clarify their potential beneficial effects in sciatica.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * radiating pain below the knee with a severity score of ≥4 on a 0-10 (nrs) in the previous 24 hours * signs of nerve root/spinal nerve involvement as indicated by at least one of the following features; myotomal weakness, dermatomal sensory disturbances (e.g. sensory loss, self-reported tingling/numbness), diminished reflexes, radiating pain exacerbation by slr exclusion criteria: * not able to read or speak norwegian. * unlikely to adhere to treatment and/ or complete follow-up (e.g ongoing serious psychiatric disease, drug abuse, plans to move) * sciatica of known cause other than disc herniation or degenerative stenosis. * neurogenic claudication, i.e. pain in the legs on walking or standing that resolves with sitting down or lumbar flexion. * symptoms indicating immediate surgery: cauda equina syndrome or a progressive large paresis. * women who attempt to conceive, are pregnant or breastfeeding. * previous episodes of asthma, urticaria or allergic-type reactions after taking aspirin or other nsaids. * active or history of peptic ulceration, gastrointestinal bleeding, or perforation. * use of drugs known to increase upper gastrointestinal adverse events in combination with naproxen: anticoagulants, aspirin (acetyl salicylic acid), serotonin reuptake inhibitors and systemic corticosteroids. * hepatic enzyme (asat/alat) values above 1,5 x upper limit of normal (uln) * renal function tests (creatinin/egfr) outside normal range * congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. * known hypersensitivity to naproxen or any of the excipients (lactose, maize starch, povidone, sodium starch glycolate, talcum, magnesium stearate, polysorbate 80) * ongoing treatment with aspirin, systemic corticosteroids, diuretics, ace-inhibitors, lithium and anticoagulants * scheduled for spinal surgery prior to end of study * reservation against intake of gelatine (the capsules contains gelatine, which among other things is produced by ingredients from pigs)
quality of life variations among adolescent females following virtual reality games approach

Conditions: Obesity and Obesity-related Medical Conditions; Menstrual Pain; Adolescent Obesity; Body Fat Composition; Obesity; Depression, Anxiety

Summary: to compare the effects of virtual reality games, aerobic exercise, and dietary modifications on quality of life among adolescent females.

the study will assess whether virtual reality games, aerobic exercise, and dietary modifications lead to significant differences in quality of life scores, and perceived exertion as measured by the borg scale. additionally, the study will evaluate whether these interventions produce varying impacts on psychological factors such as depression, anxiety, and stress, and on physical measurements like waist circumference (wc) and body fat composition.

Eligibility criteria:
inclusion criteria: * obese adolescent girls * class i obesity (body mass index from 30 to 34.99 kg/m2) * have regular menstruation * clinically and medically stable * no impairment of sensation or other neurological or psychological problems exclusion criteria: * visual and/or auditory defects * normal weight girls (body mass index from 18 to 24.99 kg/m2) or below average weight (bmi less than 18 kg/m2) or class ii \& iii obesity (bmi above 35 kg/m2) * girls with significant tightness and/or fixed deformity of lower limbs * participants with neurological disorders that affect balance or mentality (e.g. epilepsy). * girls with advanced radiographic changes include: bone destruction, bony ankylosis, knee joint subluxation, and epiphysial fracture) * congenital or acquired lower limb deformities in the lower limbs. * cardiopulmonary dysfunction. * girls under insulin therapy, uncontrolled bronchial asthma, anemia, and pathological causes of obesity (endocrinal, genetic syndromes...etc.).

Keywords: obesity adolescent girls body fat composition menstrual pain virtual reality games aerobic exercise diet adolescent obesity quality of life depression anxiety stress dass-21
fish consumption and dietary diversity in timor-leste

Conditions: Dietary Deficiency

Summary: a one-year, cluster-randomized, partially masked, controlled trial to test and compare the effects of fish aggregating devices and social and behaviour change communication on the frequency and volume of household fish consumption in upland areas of timor-leste.

this trial is a one-year, cluster-randomized, partially masked, controlled trial among families living in rural, inland timor-leste. this trial aims to test and compare the effects of two treatments, alone and in combination, on the frequency and volume of household fish consumption in upland areas as a proxy for improved dietary diversity and micronutrient intake. treatment 1 is the installation of nearshore, moored fish aggregating devices (fads) to improve catch rates with existing fishing gears. treatment 2 is social and behaviour change (sbc) activities to promote fish consumption. villages in inland communities will be randomized to receive treatment 1, treatment 2, both treatments, or neither treatment. some households with one child under five will be recruited, and data will be collected at baseline (prior to the rollout of the treatments) and endline. our study will determine the impact of an improved supply of fish, along with nutrition-oriented sbc activities, on the fish purchasing and consumption practices of rural, inland households. findings from this study are urgently needed by small island developing states in order to make policy and investment decisions on how best to improve households' diets using locally available, nutrient-dense foods such as fish. investments such as these are needed to break the cycle of malnutrition.

Eligibility criteria:
inclusion criteria: * the individual's household is situated in a village included in the study, within a 30km radius of a coastal treatment site. exclusion criteria: * the individual's household is not situated in a village included in the study.

Keywords: fish fish aggregating device malnutrition micronutrient deficiency fisheries
pathways mediating impaired postural control in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this project is to use transcranial magnetic stimulation (tms) to explore the state of excitability of corticocortical and corticofugal (cortex to spinal cord, cortex to brainstem to spinal cord) pathways that project to muscles that control the legs and trunk in people with parkinson's disease. the outcome variables will be further analyzed to understand their relationship to quantitative measures of postural instability and gait dysfunction. as such, the project can be classified as basic physiologic research. the protocol is not designed to determine if measures of corticocortical or corticofugal excitability can be used as a biomarker to predict disease progression.


Eligibility criteria:
inclusion criteria: participants with parkinson's disease * diagnosis of idiopathic pd or dystonia as determined by a movement disorders neurologist in accordance with the uk society brain bank diagnostic criteria. * age 45-80 years. * able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters. healthy older adults (control participants) * age 45-80 years (this group will be age and sex-matched to the pd group) * able to ambulate independently without the use of an assistive device (cane or walker) healthy young adults * age 21-44 years (this group will be age and sex-matched to the pd group) * able to ambulate independently without the use of an assistive device (cane or walker) exclusion criteria: * subjects who describe a history of a frequent vasovagal syncope (fainting) in response to blood, emotional stress, or sensory triggers. * subjects who are on anti-coagulant medications. * any musculoskeletal disorder that affects the ability to stand. * history of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury. * intracranial metallic or magnetic devices. * pacemaker or any implanted device. * history of surgery on blood vessels, brain or heart. * unexplained, recurring headaches or concussion within the last six months. * moderate to severe hearing impairment. * subjects who are pregnant. * dementia diagnosis * other significant neurological disorders that may affect participation or performance in the study * implanted deep brain stimulator or other neurosurgeries to treat pd.
jedi grip vs. double operator technique for axillary brachial plexus block

Conditions: Brachial Plexus Block; Ultrasound, Interventional

Summary: in this prospective randomized controlled observer-blinded study we aimed to compare the efficacy of a single operator technique so called jedi grip and conventional technique requiring double operator in ultrasound guided axillary brachial plexus block.

patients aged between 18 and 65 years, american society of anesthesiologists (asa) physical status i to ii ) undergoing elective hand, wrist and forearm surgery were prospectively enrolled. patients were randomly assigned to group c (conventional technique) or group j (jedi technique). in both groups, axillary plexus blockage was provided by applying 5cc of a mixture of 10 cc 0.5% bupivacaine and 10 cc 2% prilocaine to the ulnar, radial, median and musculocutaneous nerves. parameters such as performance time and the number of needle passes were recorded during procedure. subsequently, a blinded observer evaluated and recorded parameters related to the success of blockage. the main outcome variable was performance time and success rate (surgical anesthesia).

Eligibility criteria:
inclusion criteria: * undergoing elective hand, wrist and forearm surgery exclusion criteria: * hepatic or renal failure, serious cardiac or pulmoner disease, local or systemic infection, sepsis, coagulation disorder, neurological, muscular or psychiatric disease, body mass index (bmi) below 18.5 or above 35, drug and substance abuse, pregnancy, refusal of regional anesthesia, history of allergy to local anesthetics, mental-motor retardation (inability to consent or assess the visual analog scale(vas) pain score), preoperative long-term nsaids or opioid use and prior surgery in the axillary regions.

Keywords: brachial plexus block, ultrasound-guided, jedi grip, double operator peripheric nerve block
a long-term study of de-117 ophthalmic solution monotherapy and concomitant use of de-117 ophthalmic solution with timolol ophthalmic solution in patients with oag or oh: renge study

Conditions: Open Angle Glaucoma or Ocular Hypertension

Summary: the purposes of this study are to evaluate the long-term safety and intraocular pressure-lowering efficacy of de-117 ophthalmic solution monotherapy and concomitant use of de-117 ophthalmic solution with timolol ophthalmic solution 0.5% in patients with open angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * patients with open angle glaucoma or ocular hypertension exclusion criteria: * patients at risk of progression of visual field loss * patients with severe visual field defect * patients with any diseases that preclude participation in this study for safety reasons
combined versus successive macular hole and cataract surgery

Conditions: Macular Hole; Visual Acuity

Summary: the purpose of this study is to compare functional and anatomical results of a combined surgery and two time surgery for macular hole and cataract extraction in one hundred and twenty patients (120 eyes) with idiopathic macular hole (mh) and cataract in two academic centers.

main outcome measures were the assessment of visual acuity at 6 and 12 months,and the rate of closure of mh by oct (optical coherence tomography).

Eligibility criteria:
inclusion criteria: * macular hole stage 2,3,and 4 * visual loss * at least 18 years of age exclusion criteria: * stage of macular hole stage 1 * macular hole post traumatism or associated with retinal detachment * diabetic retinopathy * glaucoma * age-related macular degeneration * myopia \> 6 diopters * preoperative pseudophakia

Keywords: macular hole cataract surgery vitreoretinal surgery combined surgery idiopathic
a study comparing the withdrawal of steroids or tacrolimus in kidney transplant recipients

Conditions: Kidney Failure; Graft vs Host Disease

Summary: this study evaluates two different immunosuppression drug regimens in patients with a recent kidney transplant. patients initially received a regimen of sirolimus, tacrolimus and prednisone and then randomized to discontinue either tacrolimus or prednisone.


Eligibility criteria:
inclusion criteria: * end-stage renal disease, with patients scheduled to receive a kidney transplant. * women who are of childbearing potential who are not pregnant and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of study drugs. any woman becoming pregnant during the treatment period must discontinue the use of study drugs; * signed informed consent. exclusion criteria: * evidence of active systemic or localized major infection at the time of initial study drug administration; * multiple organ transplants; * any pathology or medical condition that can interfere with this protocol study proposal. other exclusion applies.

Keywords: kidney transplant
self-management and cognitive function in adults with heart failure

Conditions: Cognitive Impairment; Cardiac Disease; Heart Failure

Summary: the purpose of this study is to assess the relationship between cognitive impairment, patient self-management, health, and health service use in adults with heart failure (nyha class 2 and 3). the research questions are: 1. how is cognitive impairment (memory, attention, global and executive function) related to various aspects of impaired self-management (knowledge of adherence, adherence to sodium restriction and medications, symptom monitoring of weight changes, and decision and action to seek care)? 2. how are these relationships altered when adjusting for medical, demographic, and psychosocial factors? 3. what are the relationships among degree of cognitive impairment, quality self-management, health status, and health service use?


Eligibility criteria:
inclusion criteria: * documented systolic heart failure * nyha class ii, iii of at least 6 months duration * 50-85 years of age * has a telephone (land line) or be willing to allow a telephone installed for duration of study exclusion criteria: * history of neurological disorder or injury * moderate or severe head injury * past or current history of severe psychiatric illness; specifically, psychotic disorders and bipolar disorder * 5 year past or current history of alcohol or drug abuse * history of learning disorder or developmental disability * renal failure requiring dialysis * history of sleep apnea * current home telemonitoring program to assist w/ hf self-management * cardiac surgery \< 3 months

Keywords: cognitive impairment cognitive function hospitalization self-management cardiac disease heart failure
a study of the efficacy and safety of ziprasidone for the treatment of acute exacerbation of schizophrenia or schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (im), and to assess the effect of switching from im to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder in a latin american population.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder. * inpatients with acute exacerbation of psychotic symptoms. * patients with a minimum score of 40 on the bprs scale (1-7). exclusion criteria: * concurrent treatment with antipsychotic agents at study drug initiation (within 12 hours prior to study drug initiation); for depot agents a period of two weeks or one cycle, whichever is the longer, must occur between last administration and study drug initiation. * treatment with antidepressants or mood stabilizers within 7 days of start of ziprasidone. * patients currently receiving clozapine. * patients at immediate risk of committing harm to self or others.
acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy

Conditions: Minimal Hepatic Encephalopathy

Summary: minimal hepatic encephalopathy represents a common complication present in well-compensated cirrhotic patients that impairs patients daily functioning and health-related quality of life. acetyl-l-carnitine has been shown to be useful in improving blood ammonia and cognitive functions in cirrhotic patients with minimal hepatic encephalopathy. this study evaluated the effects of acetyl-l-carnitine treatment on health related quality of life and on depression in patients with minimal hepatic encephalopathy.


Eligibility criteria:
inclusion criteria: * all patients diagnosed as having cirrhosis at the outpatient internal medicine of the department of senescence of cannizzaro hospital (catania) were candidates for enrolment. the diagnosis of cirrhosis was based on clinical, biochemical and ultrasonographic or liver histological data. exclusion criteria: * exclusion criteria were overt hepatic encephalopathy or a history of overt he; history of recent alcohol intake; infection; recent antibiotic use or gastrointestinal bleeding; history of recent use of drugs affecting psychometric performances like benzodiazepines, antiepileptics or psychotropic drugs; a history of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension; electrolyte imbalance; renal impairment; hepatocellular carcinoma; severe medical problems such as congestive heart failure, pulmonary disease or neurological or psychiatric disorder that could influence quality of life measurement; inability to perform neuropsycological tests.

Keywords: acetyl-l-carnitine; minimal hepatic encephalopathy; quality of life; depression.
polydatin injectable (hw6) for shock treatment

Conditions: Shock, Hemorrhagic; Shock, Traumatic; Shock, Septic

Summary: hw6 can prolong animal's survival time and increase the survival rate. hw6 enhances cardiac function, improves microcirculation, and increases blood pressure and pulse pressure, and improves blood perfusion of important organs; hw6's anti-shock activity comes from a combined multiple target pharmacological effects. based on a completed phase ii trial conducted in china, hw6 can effectively treatment shock patient. this is a phase ii clinical study to further evaluate the efficacy and safety of polydatin injectable 100mg/5ml/via (hw6) in the treatment of shock in the united states. patients with traumatic/hemorrhagic shock or septic shock admitted to the emergency room or icu with systolic blood pressure \< 90mmhg, or is on vasopressor(s) for systolic blood pressure stabilization, regardless the types of completed, on-going, or projected standard of care or surgery will be recruited to participant in the trial. a total of 120 patients with traumatic/hemorrhagic shock and 120 patients with septic shock will be enrolled. for each type of shock, sixty patients each will be in test group and control group. both adult males and females aged 18-80 years are eligible. the primary clinical endpoint is the time length (tl) between the start of hw6 administration to the onset of the first treatment success, that is: the systolic blood pressure is stabilized at ≥90mmhg and map≥65mmhg for 1 hour without the use of vasopressors. several secondary endpoints and biomarkers will be measured. efficacy data will be compared using group t-test or wilcoxon log-rank test between treatment groups and placebo groups. safety data will also be reported accordingly.


Eligibility criteria:
inclusion criteria: * adult males or females aged 18-80 years. * patients with traumatic/hemorrhagic shock or septic shock admitted to the emergency room or icu with systolic blood pressure \< 90mmhg, or is on vasopressor(s) for systolic blood pressure stabilization, regardless the types of completed, ongoing, or projected standard of care or surgery. * patients (or its relative) who have signed informed consent form to voluntarily participate in this clinical study. exclusion criteria: * has known allergic constitution or history of alcohol or drug allergy. or * complicating acute cardiac failure, acute renal failure, acute liver failure or disseminated intravascular coagulation (dic). or * pregnant or lactating women. or * complicating moderate to severe craniocerebral injury. or * has known previous severe chronic disease(s) in liver, kidney, carvascualr system or central nervous system. or
micu recovery clinic

Conditions: Critical Illness; Sepsis; Respiratory Failure; ARDS

Summary: summary: emerging data demonstrate long-term morbidity and mortality in those who survive critical illness. however, there is no data regarding long-term follow-up for icu survivors. the investigators have begun the implementation of an icu recovery clinic. rationale: icu survivors are at high risk for functional, cognitive and psychiatric impairments. however, methods to mitigate these impairments and improve recovery are lacking. special follow-up clinics for survivors of critical illness have been proposed and implemented to some degree, but are uncommon.

objectives: 1. to evaluate physical function, cognitive function, and overall functional status during recovery from critical illness. 2. to evaluate anxiety, depression, and ptsd during recovery from critical illness. 3. to evaluate resilience during recovery from critical illness. 4. to evaluate healthcare utilization rates, morbidity, and mortality following critical illness. 5. added april 2016: to study the voice and swallowing function of patients following recovery from critical illness. 6. added april 2016: to study the pain of patients following recovery from critical illness. intervention: a prospective observational study of all patients who attend our icu recovery clinic. methods: patients will be identified for participation in our icu recovery clinic during their admission to the wake forest baptist medical center medical intensive care unit (micu). they will be asked to return to the icu recovery clinic within 1 month of hospital discharge. structured clinic visits as standard of care will include medication reconciliation and evaluation by a pharmacist, along with an evaluation by a clinic physician to address acute medical issues and provide counselling. they will also undergo standardized testing to evaluate physical function, cognitive function, and psychiatric function. added april 2016: they will also undergo a standardized evaluation of speech, swallow, and pain.

Eligibility criteria:
inclusion criteria: wake forest micu admission * sepsis or * respiratory failure requiring \>24 hrs of invasive mechanical ventilation * previously functional exclusion criteria: - active malignancy

Keywords: recovery icu clinic survivor physical function